The Abelson murine leukemia virus transforming gene product is a phosphorylated protein encoded by both viral and cellular sequences. This gene product has an amino-terminal region derived from the gag gene of its parent virus and a carboxyl-terminal region (abl) derived from a normal murine cellular gene. Using a combination of partial proteolytic cleavage techniques and antisera specific for gag and abl sequences, we mapped in vivo phosphorylation sites to different regions of the protein. Phosphoproteins encoded by strain variants and transformation-defective mutants of Abelson murine leukemia virus with defined deletions in the primary sequence of the abl region were compared by twodimensional limit digest peptide mapping. Specific phosphorylation pattern differences for wild-type and mutant proteins probably represented deletions of specific phosphate acceptor sites in the abl region. An in vitro autophosphorylation activity copurified with the Abelson murine leukemia virus protein from transformation-competent strains. A peptide analysis of such in vitro reactions demonstrated that these phosphorylation sites were restricted to the aminoterminal region, and the specific sites appeared to be unrelated to the sites found on proteins phosphorylated in vivo. Thus, the autophosphorylation reaction probably correlates with an activity important in transformation, but the specific end product in vitro bears little resemblance to its function in vivo.
Abelson murine leukemia virus (A-MuLV) is a member of an increasingly large group of replication-defective rapidly transforming retroviruses (9, 27) . Derived from the replication-competent Moloney murine leukemia virus by recombination with a normal cellular gene, AMuLV expresses transforming activity for both established fibroblast lines in vitro and pre-B cells in vitro and in vivo (1, 2, (17) (18) (19) 24) . AMuLV retains homology to Moloney murine leukemia virus at the ends of its genome but contains sequences derived from a cellular gene intemally (7, 15, 26, 31, 32) . These internal sequences are referred to as the abl region. The nucleic acid recombination in A-MuLV results in the production of a fused protein containing an amino-terminal region precisely homologous to Moloney murine leukemia virus gag gene subregions p15 and p12 and a portion of p30 and a carboxyl-terminal region derived from the acquired cellular sequences. An auto-phosphorylation activity specific for tyrosine residues copurifies with the A-MuLV protein (28) . No other A-MuLV-specific primary translation product has been identified. Deletion and premature termination mutants in the carboxyl-terminal abl region which show parallel changes in transforming potential and the level of the in vitro phosphotyrosine kinase activity (20, 21, 23, 29) strongly suggest that this protein contains the transforming function for A-MuLV.
The A-MuLV protein is a phosphoprotein in vivo (16, 32) . Defining the role of the cellular protein kinases or the auto-phosphorylation activity of the A-MuLV protein in these in vivo post-translational modifications could aid in our understanding of the control of the function of this protein. In this study we began such an analysis by identifying the regions and specific sites on the A-MuLV protein which are phosphorylated, as well as the specific differences expressed by mutant strains of A-MuLV.
MATERIALS AND METHODS Cells and viruses. Each strain of A-MuLV was isolated in a transformed nonproducer clone of NIH/ 3T3 cells (20, 21, 24 (20, 28, 32 Two-dimensional peptide mapping. Different A-MuLV proteins labeled with 32P from in vitro kinase reactions or in vivo labeling were isolated by immunoprecipitation and gel electrophoresis, visualized by autoradiography, and excised from dried gels. Gel pieces were processed and limit digested with a-chymotrypsin as previously described (5) . Samples were electrophoresed in the first dimension on thin-layer cellulose sheets in formic acid-acetic acid-water (5:15: 80) and then chromatographed in the second dimension by ascending chromatography in acetic acid-pyridine-butanol-water (5:25:32.5:20) containing 7.2% PPO (2,5-diphenyloxazole; Eastman Chemicals), as previously described (5, 6) .
RESULTS
Summary of A-MuLV strains. The relative genome structures deduced from Southern blot analyses (7, 8) demonstrated that the strain P160 genome (6.3 kilobases) contained a region of 800 bases in the abl-specific region that was not found in strain P120 or the other strains. The genomes of strains P120, P100, P90, and P85 were the same size (5.5 kilobases), and the smaller primary translation products of these strains were probably due to premature stop codons caused by single base changes or very small deletions. Strain P92 was a true transformation-defective mutant. Its genome had an additional deletion of 700 bases in the center of the abl sequences, which resulted in a total loss of transforming activity for fibroblasts and lymphoid cells and a loss of in vitro kinase activity (29) .
All strains appeared to have identical Moloney murine leukemia virus-derived gag gene sequences at the 5' ends of their genomes and to share extensive regions of the abl sequences. These observations were supported by immunoprecipitation analyses in which we used rabbit monospecific antisera against the gag gene products p15, p12, and p30 and a tumor regressor serum (anti-AbT) specific for the abl-encoded region (20, 21, 30) .
Limited proteolysis of A-MuLV proteins. From the nucleic acid structures of the different A-MuLV strains, we predicted a common aminoterminal region of about 50,000 daltons for all of the A-MuLV proteins (comprised of gag gene and some abl gene sequences) and carboxy-terminal regions of varying lengths and compositions (derived entirely from abl sequences).
We used partial proteolytic cleavage ( Fig. 1 (32) . (a) A portion of each preparation was denatured, electrophoresed on a 10% polyacrylamide gel, and developed by fluorography (3, 13) . (b) Equivalent portions (representing 2.0 1l of goat antiserum) were denatured in SDS gel sample buffer (10 I), diluted with 10 ,Ll of S. aureus V8 protease (10 ,ug/ml) in 50 mM Tris (pH 6.8), and reacted at 37°C for 30 min. The reactions were terminated by adding 10 ,tl of twofoldconcentrated gel sample buffer and heating at 70°C for 10 min; the resultingpreparations were then analyzed as described above. (c and d) Equal numbers of unlabeled cells were extracted, clarified, and immunoprecipitated as described above; then, the A-MuLVproteins were labeled with [y-32P]ATP by the auto-phosphorylation reaction (28) . Samples were treated as described above for control (c) and protease-digested (d) comparisons. The positions ofprotein molecular weight markers, including bovine serum albumin (molecular weight, 68,000 [68K]), heavy-chain immunoglobulin (50,000), and light-chain immunoglobulin (25,000), are also shown.
ducer NIH/3T3 fibroblast clones by immunoprecipitation in 0.5% SDS buffer and subjected them to control conditions (Fig. la) or to digestion with S. aureus V8 protease (Fig. lb) . These preparations (Fig. la) contained small amounts of a common, naturally occurring fragment of 80,000 daltons, as well as the expected initial 90,000-, 120,000-, and 160,000-dalton proteins of the different A-MuLV strains. Each cleaved preparation (Fig. lb) Interestingly, we found a very similar pattern of fragments for methionine-and ATP-labeled proteins by using proteases having quite different specificities, such as chymotrypsin, thernolysin, and pronase. This suggested that a particularly protease-sensitive region was exposed preferentially even under the SDS denaturing conditions used in these studies. Similar results were obtained with strains P100 and P85 (data not shown).
To document the origin of these specific fragments further, we oriented them by using antisera specific for certain subregions of the gag gene (specifically, the p15 and p12 proteins) and antiserum specific for the abl sequences (Fig. 2) . Protein P120 was labeled by the in vitro autophosphorylation reaction with [y-32P]ATP and then subjected to control conditions (Fig. 2 The cleavage reactions were stopped by heating, and then portions of the preparations were diluted and immunoprecipitated as described above with normal rabbit serum (Fig. 2a) , rabbit anti-p15 (the most amino-terminal portion of the gag gene and P120) (Fig. 2b) , normal mouse serum (Fig. 2c) , and mouse anti-AbT (specific for the abl-derived portion of P120) (Fig. 2d) .
Even after heating in SDS, enough antigenic structure was retained so that labeled protein P120 and protein fragments could be recognized by the specific antibodies. The 45,000-dalton set of fragments labeled by the auto-phosphorylation reaction appeared to represent a common amino-terminal region which contained the gag sequence and a portion of the abl sequences.
Similar studies with anti-p12 antiserum gave the same results (see below). Additional control immunoprecipitations with anti-plO antiserum (plO was a portion of the gag gene not found in A-MuLV proteins) were negative (data not shown). Such immunoprecipitation studies could not prove that the precise amino terminus was present in the 45,000-dalton fragment since small cleavages near the end could have left enough of the p15 sequence intact to be recognized for immunoprecipitation. Some indirect support for the presence of the precise amino terminus in this fragment came from the fact that protein P120 labeled with [3H]acetate gave rise to a labeled 45,000-dalton fragment (but not the 75,000-dalton fragment) after cleavage with S. aureus V8 (data not shown). The amino terminus of the gag gene protein p15 is known to be blocked by acetylation (14) and should mark this end of the protein P120 molecule as well. Conversion of the label to forms other than the expected acetate group could not be ruled out. Figure 3 shows the orientations of the carboxyl-terminal fragments of 45,000 daltons for strain P90, 75,000 daltons for strain P120, and 115,000 daltons for strain P160.
[35S]methioninelabeled proteins were subjected to control conditions (Fig. 3a) or to cleavage with S. aureus V8 protease (Fig. 3b) , and the total products were analyzed by gel electrophoresis. Portions of control digestions (Fig. 3c) and S. aureus V8-cleaved preparations (Fig. 3d) were diluted and immunoprecipitated with anti-AbT. The carboxyl-terminal fragments of 45,000 daltons (lanes A), 75,000 daltons (lanes B), and 115,000 daltons (lanes C) were recovered with anti-AbT (Fig. 3d ). An additional fragment of about 60,000 daltons was found only in digests of strain P160 (Fig. 3d, product serum, did not precipitate any of these carboxyl-terminal fragments (data not shown).
In vitro and in vivo phosphorylation sites. To begin a study of phosphorylation sites (Fig. 4) , we compared protein P120 preparations labeled by in vitro auto-phosphorylation ( Fig.   4A and B) and labeled in vivo with 32Pi ( Fig. 4C and D). Each preparation was subjected to control incubation (lanes 1) or to digestion with increasing amounts of S. aureus V8 protease (lanes 2 and 3) and then diluted and immunoprecipitated with anti-p12 serum (Fig. 4A and C) or anti-AbT (Fig. 4B and D) . Most striking were the similar patterns obtained with the two labeled preparations. The predominant fragments in both in vitro-and in vivo-labeled preparations included the amino-terminal 45,000-dalton bands which reacted with anti-p12 serum and anti-AbT and a series of smaller fragments (about 15,000 to 20,000 daltons), which were reactive only with anti-p12 serum (Fig. 4A, lane  3, and Fig. 4C, lane 3) . These small fragments were not precipitable with anti-p15 serum (data not shown). A small amount of the 75,000-dalton fragment from the carboxyl-terminal (abl) region was recovered with anti-AbT from the in vivo-labeled preparation only (Fig. 4D, lane 2) .
The 75,000-dalton fragment was not recovered from any of the in vitro-labeled preparations. This 75,000-dalton fragment was more sensitive to further proteolysis.
The abl-specific carboxyl-terminal fragments (75,000-dalton fragment from protein P120 and 115,000-and 60,000-dalton fragments from protein P160) could be recovered in higher yields by using a lower ratio of protease to substrate or by following the kinetics of digestion (Fig. 5) . This was true when 32Pi-labeled P120 (Fig. 5A) or P160 (Fig. 5B) ial migrated some of these were labeled on serine, and some abeled pep-were labeled on tyrosine (25, 28 ; unpublished included at data). Very similar observations were made by which were Reynolds et al. (16) and Sefton et al. (25) , who iere were at also noted the lack of common sites for in vivoany did not and in vitro-labeled P120. Thus, although the atography); regional localization was similar for a portion of the phosphates on in vitro-and in vivo-labeled P120, the specific sites were distinct. Two-dimensional peptide maps of in vitro-labeled protein P160 and P90 preparations were indistinguishable from the map of protein P120 (data not shown 
DISCUSSION
The results of one-and two-dimensional peptide mapping studies of the various A-MuLV proteins are in good agreement with the structures predicted by nucleic acid analyses (7, 8 (Fig. 7, peptide 4) . although it is possible that strain P92 may carry out some auto-phosphorylation in vivo. The number and possible functions of the cellular kinases that recognize the abl-specific sequences remain unknown. The in vitro tyrosine-specific auto-phosphorylation activity labels within the amino-terminal region from 40,000 to 45,000 daltons, and a number of sites can be utilized. It is not known whether all of these sites fall within the gag region. More extensive digestions of the 45,000-dalton amino-terminal piece do generate smaller labeled fragments that immunoprecipitate with anti-gag protein sera but not with anti-AbT (Fig. 4) . This suggests that some of these sites are within the gag region, but we cannot rule out the possibility of some labeling in the abl sequences. The specific peptides labeled bear little resemblance to the peptides in in vivo phosphate-labeled preparations (Fig. 6 ). It seems likely that the in vitro kinase activity measured in immunoprecipitates or on partially purified protein P120 (28) represents an activity important in vivo but not the precise reaction found within cells. Deciphering the role of the A-MuLV kinase activity in vivo has been approached by several groups. Hunter (10) Although the roles of specific in vivo phosphorylation sites on the A-MuLV protein itself are not known, the possibility that cellular protein kinases may modulate A-MuLV kinase activity needs further investigation (12, 22) .
